Gabapentin Tablet, Film Coated
Product Images NDC 70518-2098

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-2098). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 600mg 70518 2098 01

Gabapentin 600 mg film-coated tablets packaging label showing a quantity of 180 tablets. The label includes the proprietary name Gabapentin, the dosage strength 600 mg, and the dosage form as tablet. It is repackaged by RemedyRepack Inc. The label also features a QR code, NDC number 70518-2098-01, and manufacturer information for ACI Healthcare USA, Inc.*

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin 600 mg film-coated tablets in a 30-count package. The label shows the brand name Gabapentin with the strength highlighted, specifies 'Tablet' and quantity of 30. It includes repackager information, RemedyRepack Inc., with directions to see the package insert and storage instructions. The label mentions prescription use only and notes the manufacturer as ACI Healthcare USA, Inc.*

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustration showing the formula for calculating creatinine clearance (CLCr), which incorporates age, weight, serum creatinine, and a gender adjustment factor for females.*

FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of Gabapentin showing a cyclohexane ring attached to a carbon with an amino (CH2NH2) and a carboxyl (CH2CO2H) group.*

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph comparing mean pain scores over an 8-week period between placebo and gabapentin 3600 mg/day. The graph shows a 4-week dose titration period followed by a 4-week fixed dose period, with mean pain scores on the vertical axis and weeks on the horizontal axis. Gabapentin shows a decreasing trend in pain scores compared to placebo.*

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph showing mean pain scores over seven weeks for three groups: placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis measures mean pain score from 0 to 10. Both gabapentin groups show a decrease in pain score over time compared to placebo.*

FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies,' showing results from two studies. Study 1 compares placebo (12%) versus GBP 3600 (29%). Study 2 compares placebo (14%), GBP 1800 (32%), and GBP 2400 (34%), with statistical significance indicated for GBP groups.*

FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot comparing three different studies labeled 'studya', 'studyb', and 'studyc'. The x-axis represents daily dose in milligrams (600, 900, 1200, 1800 mg), and the y-axis shows difference percentage ranging approximately from 2% to 22%. Each study's data points are depicted with different colored squares, illustrating differences at various dosing levels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.